New Ultra-Sensitive Assays Aim to Improve Early Detection of Alzheimer’s and Parkinson’s Disease
Three new immunoassays targeting key neurodegeneration biomarkers require just 1 µL of plasma and run on standard laboratory instruments.
Read MorePosted by CLP Edit Staff | Mar 23, 2026 | Dementias & Alzheimer’s, Immunoassay |
Three new immunoassays targeting key neurodegeneration biomarkers require just 1 µL of plasma and run on standard laboratory instruments.
Read MorePosted by CLP Edit Staff | Feb 18, 2026 | Disease States |
Researchers have identified blood biomarkers that may enable detection of Parkinson’s disease up to 20 years before symptoms.
Read MorePosted by CLP Edit Staff | Dec 18, 2025 | Disease States |
MicroRNA analysis could enable earlier detection of both sporadic and familial cases of amyotrophic lateral sclerosis.
Read MorePosted by CLP Edit Staff | Dec 1, 2025 | Dementias & Alzheimer’s |
The financing will accelerate clinical validation and commercial readiness of brain-derived blood biomarkers based on circular RNA technology.
Read MorePosted by CLP Edit Staff | Nov 26, 2025 | Disease States |
The targeted assay detects X-linked dystonia-parkinsonism cases that standard sequencing methods have missed.
Read More